La mia nuova descrizione qui!
Price of a print issue: €25.00
AIM: The effects of lauromacrogol as a sclerosing agent were evaluated on rabbit thyroid tissue.
MATERIAL AND METHODS: Twelve rabbits were divided into two equal groups. Intra-thyroid injections of 0.1 ml lauromacrogol
were administered in the study group and 0.1 ml physiologic serum in the control group. The blood levels of
free T3, free T4, TSH, postoperative adhesions and histopathologic differences of the thyroid tissues were evaluated.
RESULTS: The values of serum free T3, free T4 and TSH levels did not differ significantly (p>0.05), but the free T3
levels were significantly different in the inter-group analysis (p=0.020). Postoperative macroscopic adhesion scores did not
differ significantly (p>0.05). In the histopathologic evaluation, the inflammation and fibrosis scores were significantly
higher in the study group (p=0.003).
DISCUSSION: In our study, we found two important outcomes. Firstly, tests of thyroid function were not significantly different
between the control and study groups. This important finding suggests lauromacrogol can be safely used without
the risk of hypothyroidism or hyperthyroidism. Secondly, the Erlich-Hunt Model histopathologic evaluation results revealed
that inflammation and fibrosis were significantly increased in the study group. This finding shows lauromacrogol can be
effectively used to treat thyroid nodules by means of fibrosis.
CONCLUSIONS: Lauromacrogol causes fibrosis in thyroid tissue without significant perithyroidal adhesion formation and
functional differences. Treatment of nodular thyroid disease with lauromacrogol may be safe.